

Our Partners:

Sanofi-aventis closely collaborates with public healthcare agencies such as:

- ▶ World Health Organization/International Medicinal Products Anti-counterfeiting Taskforce (WHO/IMPACT): <http://www.who.int/impact/en>
- ▶ European Agency for the Evaluation of Medicinal Products (EMA): <http://www.emea.europa.eu>
- ▶ Food and Drug Administration (FDA) in the United States: <http://www.fda.org>
- ▶ Medicines and Healthcare products Regulatory Agency (MHRA): <http://www.mhra.gov.uk>
- ▶ Federal Institute for Drugs and Medical Devices (Bfarm): <http://www.bfarm.de>
- ▶ Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS – French Agency for the Safety of Medicines): <http://agmed.sante.gouv.fr>
- ▶ Collaboration with payers (i. e. Health Maintenance Organisation (HMO), Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (CNAMTS), etc.)

We also work in close collaboration with government administrations, customs, police, pharmacists, wholesalers and other pharmaceutical companies to investigate suspected counterfeiters

The problem has to be solved on a **global** level, but **Europe has an essential leading role to play** since it can, and must, be the driver of any action

For more information, please contact:

Ingrid Goerg-Armbrrecht
Global Product Communication – Metabolism, sanofi-aventis
ingrid.goerg-armbrecht@sanofi-aventis.com



Sanofi-aventis **Commitment** to Protecting Patient's Health



Facts:

- ▶ All pharmaceutical products are potentially concerned, innovative drugs and generics alike
- ▶ Counterfeiting is a vile and serious **criminal offence** that puts human lives at risk and undermines the credibility of health systems
- ▶ Drug counterfeiting is a **public health menace**, proliferating at vast speed with dozens of new instances appearing every day in all parts of the globe
- ▶ Drug counterfeiters must be prosecuted as such since their products can have **dramatic consequences** on patients' lives
- ▶ In Europe, **parallel trade circuits** may be used by counterfeiters to distribute their fake products
- ▶ All pharmaceutical companies are concerned, producers of innovative drugs or generics alike

Our Commitment:

- ▶ Addressing public healthcare needs and acting responsibly in all aspects of our business
- ▶ Protecting public health through regulation and helping people who use our products to understand their risk/benefit ratio
- ▶ Ensuring the highest quality of all sanofi-aventis medicinal products



Our Response:

- ▶ Using **innovative technology** for all sanofi-aventis product packaging to make the manufacturing of counterfeits **more difficult** and to **facilitate detection**
- ▶ Creation of **global counterfeit coordination team** including operations, legal, regulatory, manufacturing, quality and security departments
- ▶ Local correspondents in **every country**
- ▶ **Active** communication
- ▶ Creation of **brand new laboratory** dedicated to analyse and identify counterfeit medicines



sanofi aventis

Because health matters